Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Healthlead Public Company Limited (HL.BK)
Nonthaburi, TH
Healthlead Public Company Limited, along with its subsidiaries, specializes in the creation, sourcing, and distribution of a wide array of health-related goods. This portfolio encompasses pharmaceuticals, medicinal preparations, beauty aids, nutritional supplements, and medical devices. Their offerings also include hygiene products like disinfectants and deodorizers, notably masks, sold under brand names such as iCare, Pharmax, vitaminclub, and Super Drug. Furthermore, nutritional supplements are marketed under the PRIME and Besuto brands. Diversifying its operations, the company engages in property leasing, event planning, restaurant management, and operates its own medical clinic. It maintains a retail footprint through 28 pharmacy locations: 11 iCare, 13 Pharmax, 3 vitaminclub, and 1 Super Drug. The company was founded in 2018 and has its principal office in Nonthaburi, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.85% | -1.69% | -7.20% | -18.31% | -15.94% | -19.44% | -10.77% | -60.81% | -40.82% | -40.82% | -40.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+12.7% ★ Q1'26: +2.7% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+0.0% Q1'26: -4.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+4.7% ★ Q1'26: +5.6% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+2.8% Q1'26: +2.6% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+6.6% ★ Q1'26: +6.7% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-1.3% ★ Q1'26: -4.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×2.06× ★ Q1'26: 2.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
1.64B
est: 1.83B (-10.8%)
|
1.98B
est: 1.84B (+7.7%)
|
2.23B
est: 2.20B (+1.5%)
|
2.37B
2.37B – 2.37B
+8.0% YoY
|
| EBITDA |
159.05M
est: 181.36M (-12.3%)
|
187.15M
est: 181.45M (+3.1%)
|
154.29M
est: 217.05M (-28.9%)
|
234.45M
234.45M – 234.45M
+8.0% YoY
|
| EBIT |
103.02M
est: 120.93M (-14.8%)
|
110.07M
est: 120.99M (-9.0%)
|
61.57M
est: 144.73M (-57.5%)
|
156.33M
156.33M – 156.33M
+8.0% YoY
|
| Net Income |
74.68M
est: 75.22M (-0.7%)
|
78.26M
est: 83.23M (-6.0%)
|
77.86M
est: 99.34M (-21.6%)
|
110.08M
110.08M – 110.08M
+10.8% YoY
|
| SGA |
306.94M
est: 336.10M (-8.7%)
|
410.04M
est: 336.26M (+21.9%)
|
439.93M
est: 402.23M (+9.4%)
|
434.48M
434.48M – 434.48M
+8.0% YoY
|
| EPS |
0.27
est: 0.28 (-3.6%)
|
0.29
est: 0.31 (-6.5%)
|
0.29
est: 0.37 (-21.6%)
|
0.41
0.41 – 0.41
+10.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Araya Tantanasin | CFO, Company Secretary & Director | — | female |
| Bussakorn Amphankao | Human Resource Director | — | female |
| Mataya Bhandhukanonda | President of Executive Board & Vice Chairman of the Board | — | female |
| Nattanan Meadto | Director of Accounting | — | female |
| Pattarawan Siripongvilai | Marketing & Sales Promotion Director | — | female |
| Supakorn Bhandhukanonda | CEO, Acting COO & Director | — | male |
| Wanwimol Jongsuriyaphas | Head of Internal Audit | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HL.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
